Volume 15, Issue 4 (Volume 15, No 4 2025)
jdc 2025, 15(4): 235-244 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hamzelou S, Jafari F, Nasimi M. Evaluating the treatment history and its’ associated factors in psoriasis patients who received biologic treatment. jdc 2025; 15 (4) :235-244
URL: http://jdc.tums.ac.ir/article-1-5757-en.html
URL: http://jdc.tums.ac.ir/article-1-5757-en.html
1- Department of Dermatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran , dr.hamzelou@gmail.com
2- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3- Department of Dermatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3- Department of Dermatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (93 Views)
Background and aim: In the severe cases psoriasis, there is a need for biologic treatments which target the immunological responses contributing to the disease pathophysiology. There is no study in definite indications for the treatment choice and the time to start the biologic treatment in Iranian psoriasis patients.
Methods: We designed a cross-sectional study and evaluated all psoriasis patients who had received biologic treatment. After determining the patients who were eligible to participate in the study, their records were studied and analyzed.
Results: 50 patients with the mean age of 42.86 (SD=14.33) participated in the study. Twenty-five patients had received phototherapy for the treatment of psoriasis. All patients had received topical agents and 47 (94%) had received systemic treatment. Adalimumab was the most common biologic treatment used for the treatment of psoriasis patients (74%). 24% of patients had received Infliximab and 4% had received Etanercept.
Conclusion: 50 patients with the mean age of 42.86 (SD=14.33) participated in the study. Twenty-five patients had received phototherapy for the treatment of psoriasis. All patients had received topical agents and 47 (94%) had received systemic treatment. Adalimumab was the most common biologic treatment used for the treatment of psoriasis patients (74%). 24% of patients had received Infliximab and 4% had received Etanercept.
Methods: We designed a cross-sectional study and evaluated all psoriasis patients who had received biologic treatment. After determining the patients who were eligible to participate in the study, their records were studied and analyzed.
Results: 50 patients with the mean age of 42.86 (SD=14.33) participated in the study. Twenty-five patients had received phototherapy for the treatment of psoriasis. All patients had received topical agents and 47 (94%) had received systemic treatment. Adalimumab was the most common biologic treatment used for the treatment of psoriasis patients (74%). 24% of patients had received Infliximab and 4% had received Etanercept.
Conclusion: 50 patients with the mean age of 42.86 (SD=14.33) participated in the study. Twenty-five patients had received phototherapy for the treatment of psoriasis. All patients had received topical agents and 47 (94%) had received systemic treatment. Adalimumab was the most common biologic treatment used for the treatment of psoriasis patients (74%). 24% of patients had received Infliximab and 4% had received Etanercept.
Type of Study: Research |
Subject:
General
Received: 2025/04/4 | Accepted: 2024/02/4 | Published: 2024/02/4
Received: 2025/04/4 | Accepted: 2024/02/4 | Published: 2024/02/4
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
